GMAB
Genmab AS
35.60$
+0.6%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | 0.0% | 0.0% | 1.4% | 4.6% | 8.3% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.6% | 95.4% | 91.7% | |
| 59.5% | 43.0% | 36.4% | 37.0% | 47.3% | 44.5% | 31.0% | 49.7% | 38.3% | 46.3% | 45.3% | 41.9% | |
| 9.4% | 8.1% | 5.6% | 6.2% | 7.1% | 6.4% | 6.5% | 15.2% | 18.4% | 20.0% | 17.6% | 16.8% | |
| 68.8% | 35.5% | 42.0% | 43.2% | 54.4% | 50.8% | 37.6% | 64.9% | 56.8% | 66.3% | 64.3% | 58.1% | |
| 31.2% | 64.5% | 58.0% | 56.8% | 45.6% | 49.2% | 62.4% | 35.1% | 43.2% | 32.3% | 31.1% | 33.6% | |
| 0.5% | 0.0% | 0.0% | 0.1% | 0.0% | 0.1% | 0.1% | 0.2% | 0.1% | 0.2% | 0.6% | 1.6% | |
| 35.0% | 66.9% | 62.2% | 45.0% | 53.3% | 53.3% | 58.4% | 46.5% | 47.9% | 34.2% | 42.6% | 32.4% | |
| -0.5% | -0.5% | -3.1% | -1.7% | 4.6% | 12.9% | 11.3% | 11.4% | 10.3% | 7.8% | 6.1% | 6.5% | |
| 35.4% | 67.4% | 65.4% | 46.7% | 48.7% | 40.4% | 47.1% | 35.1% | 37.6% | 26.4% | 36.4% | 25.9% | |
| 36.9% | 69.7% | 64.5% | 62.9% | 56.2% | 56.0% | 60.9% | 49.7% | 50.6% | 36.1% | 45.0% | 35.9% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.